Apollomics Inc. (APLM)
6.00
-0.71 (-10.58%)
At close: Apr 04, 2025, 3:57 PM
5.33
-11.17%
After-hours: Apr 04, 2025, 07:42 PM EDT
Company Description
Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia.
It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain.
The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019.
Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.
Apollomics Inc.

Country | United States |
IPO Date | Nov 26, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 45 |
CEO | Dr. Guo-Liang Yu Ph.D. |
Contact Details
Address: 989 East Hillsdale Blvd Foster City, California United States | |
Website | https://www.apollomicsinc.com |
Stock Details
Ticker Symbol | APLM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001944885 |
CUSIP Number | n/a |
ISIN Number | KYG0411D1079 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Guo-Liang Yu Ph.D. | Co-Founder, Chief Executive Officer & Executive Chairman |
Dr. Matthew James Plunkett Ph.D. | Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 03, 2025 | 20-F | Filing |
Apr 03, 2025 | 6-K | Filing |
Mar 31, 2025 | 6-K | Filing |
Jan 10, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Dec 20, 2024 | 6-K | Filing |
Dec 10, 2024 | 6-K | Filing |
Nov 14, 2024 | 6-K | Filing |
Nov 01, 2024 | 6-K | Filing |
Aug 15, 2024 | SC 13D/A | [Amend] Filing |
Aug 14, 2024 | 6-K | Filing |